Patel, K., Shah, N., Tan, A., Cowan, A. J., Turtle, C. J., Hofmeister, C. C., … Perales, M.-A. (2022). Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. In Blood (Vol. 140, pp. 10357–10359). American Society of Hematology. https://doi.org/10.1182/blood-2022-162539

Patel, Krina, Nina Shah, Alan Tan, Andrew J. Cowan, Cameron J. Turtle, Craig C. Hofmeister, Taewoong Choi, et al. “Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies.” In Blood, 140:10357–59. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-162539.

Patel K, Shah N, Tan A, Cowan AJ, Turtle CJ, Hofmeister CC, et al. Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. In: Blood. American Society of Hematology; 2022. p. 10357–9.

Patel, Krina, et al. “Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 10357–59. Crossref, doi:10.1182/blood-2022-162539.

Patel K, Shah N, Tan A, Cowan AJ, Turtle CJ, Hofmeister CC, Choi T, Saeed H, Chavez JC, Pianko MJ, Gandhi M, Chaudhry SA, Lee Z, Dixit N, Fanton C, Wang X, Xu H, Marcondes MQ, Tagliaferri MA, Zalevsky J, Perales M-A. Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood. American Society of Hematology; 2022. p. 10357–10359.